Verrica Pharmaceuticals Inc (VRCA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $61.16M
Last updated: Nov 17, 2026 at 10:43 AM ET
Verrica Pharmaceuticals Inc (VRCA) Earnings: Report Dates and Results
Verrica Pharmaceuticals (VRCA) is expected to report earnings on Mar 8, 2027. In the quarter ended Sep 30, 2026, Verrica Pharmaceuticals reported EPS of -$0.58, below the -$0.50 estimate. It beat the EPS estimate in 6 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
VRCA has an expected report date of Mar 8, 2027.
VRCA Earnings Call
The latest VRCA earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 34 quarters below that had an estimate, VRCA beat 17, missed 15 and matched 2. Revenue for the quarter ended Sep 30, 2026 was $6.91M, down 51.8% from $14.34M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.58 | -$0.50 | -$0.54 - -$0.46 | -16.00% | Miss | N/A | 4 | 1 up, 0 down | Nov 12, 2026 | $6.91M |
| Jun 30, 2026 | -$0.54 | -$0.47 | -$0.50 - -$0.42 | -14.89% | Miss | -316.0% | 3 | 0 up, 1 down | Aug 6, 2026 | $5.86M |
| Mar 31, 2026 | -$0.45 | -$0.59 | -$0.59 - -$0.59 | +22.98% | Beat | N/A | 2 | 0 up, 1 down | May 12, 2026 | $5.02M |
| Dec 31, 2025 | -$0.51 | -$0.64 | -$0.85 - -$0.43 | +20.31% | Beat | N/A | 2 | 0 up, 0 down | Mar 11, 2026 | $5.09M |
| Sep 30, 2025 | -$0.03 | -$0.06 | N/A | +50.00% | Beat | N/A | 3 | 1 up, 1 down | Nov 14, 2025 | $14.34M |
| Jun 30, 2025 | $0.25 | -$0.83 | -$1.10 - -$0.70 | +130.12% | Beat | N/A | 3 | 0 up, 0 down | Aug 12, 2025 | $12.70M |
| Mar 31, 2025 | -$1.00 | -$1.36 | -$2.30 - -$0.90 | +26.47% | Beat | N/A | 5 | 1 up, 0 down | May 13, 2025 | $3.44M |
| Dec 31, 2024 | -$0.20 | -$0.24 | -$0.29 - -$0.19 | +16.82% | Beat | N/A | 5 | 2 up, 0 down | Mar 11, 2025 | $344000 |
| Sep 30, 2024 | -$4.90 | -$3.87 | -$4.10 - -$3.30 | -26.61% | Miss | N/A | 3 | 1 up, 0 down | Nov 4, 2024 | N/A |
| Jun 30, 2024 | -$3.70 | -$4.02 | -$4.70 - -$3.60 | +7.96% | Beat | N/A | 5 | 0 up, 0 down | Aug 14, 2024 | $5.18M |
| Mar 31, 2024 | -$4.40 | -$4.40 | -$5.10 - -$2.90 | 0.00% | In line | N/A | 4 | 0 up, 0 down | May 13, 2024 | $3.83M |
| Dec 31, 2023 | -$0.53 | -$0.53 | -$0.64 - -$0.43 | 0.00% | In line | N/A | 5 | 0 up, 0 down | Feb 29, 2024 | $1.99M |
| Sep 30, 2023 | -$5.40 | -$3.90 | -$4.90 - -$2.20 | -38.46% | Miss | -1688.2% | 6 | 0 up, 0 down | Nov 9, 2023 | $2.92M |
| Jun 30, 2023 | -$2.40 | -$2.00 | -$2.50 - -$1.70 | -20.00% | Miss | N/A | 5 | 1 up, 0 down | Aug 8, 2023 | $182000 |
| Mar 31, 2023 | -$1.50 | -$1.70 | -$2.20 - -$1.60 | +11.76% | Beat | N/A | 4 | 0 up, 0 down | May 9, 2023 | $37000 |
| Dec 31, 2022 | -$0.14 | -$0.19 | -$0.21 - -$0.17 | +26.32% | Beat | N/A | 4 | 0 up, 0 down | Mar 6, 2023 | $68000 |
| Sep 30, 2022 | $0.34 | -$1.00 | -$2.50 - $0.20 | +134.00% | Beat | N/A | 4 | 0 up, 0 down | Nov 7, 2022 | $8.32M |
| Jun 30, 2022 | -$3.70 | -$3.20 | N/A | -15.63% | Miss | N/A | N/A | 3 up, 0 down | Aug 11, 2022 | $214000 |
| Mar 31, 2022 | -$3.10 | -$4.47 | -$5.70 - -$3.70 | +30.65% | Beat | N/A | 5 | 0 up, 0 down | May 9, 2022 | $431000 |
| Dec 31, 2021 | -$0.35 | -$0.50 | -$0.53 - -$0.46 | +30.00% | Beat | N/A | 4 | N/A | Mar 2, 2022 | N/A |
| Sep 30, 2021 | -$4.70 | -$5.10 | -$5.70 - -$4.50 | +7.84% | Beat | N/A | 5 | N/A | Nov 12, 2021 | N/A |
| Jun 30, 2021 | -$4.30 | -$4.07 | -$4.50 - -$3.50 | -5.65% | Miss | N/A | 5 | N/A | Aug 10, 2021 | N/A |
| Mar 31, 2021 | -$0.40 | -$0.34 | -$0.39 - -$0.31 | -16.62% | Miss | N/A | 4 | N/A | May 7, 2021 | $12.00M |
| Dec 31, 2020 | -$0.52 | -$0.42 | -$0.48 - -$0.38 | -23.81% | Miss | N/A | 4 | N/A | Mar 4, 2021 | N/A |
| Sep 30, 2020 | -$4.20 | -$4.33 | -$5.20 - -$3.40 | +3.00% | Beat | N/A | 4 | N/A | Nov 9, 2020 | N/A |
| Jun 30, 2020 | -$3.80 | -$4.60 | -$4.70 - -$4.20 | +17.39% | Beat | N/A | 4 | N/A | Aug 5, 2020 | N/A |
| Mar 31, 2020 | -$0.39 | -$0.38 | -$0.43 - -$0.35 | -2.63% | Miss | N/A | 3 | N/A | May 7, 2020 | N/A |
| Dec 31, 2019 | -$3.10 | -$2.95 | -$3.00 - -$2.90 | -5.08% | Miss | N/A | 2 | N/A | Mar 13, 2020 | N/A |
| Sep 30, 2019 | -$2.40 | -$2.70 | -$3.20 - -$2.20 | +11.11% | Beat | N/A | 2 | N/A | Nov 6, 2019 | N/A |
| Jun 30, 2019 | -$2.80 | -$3.40 | -$3.40 - -$2.60 | +17.65% | Beat | N/A | 2 | N/A | Aug 7, 2019 | N/A |
| Mar 31, 2019 | -$3.00 | -$2.85 | -$2.90 - -$2.80 | -5.26% | Miss | N/A | 2 | N/A | May 7, 2019 | N/A |
| Dec 31, 2018 | -$0.30 | -$0.27 | -$0.28 - -$0.26 | -11.11% | Miss | N/A | 3 | N/A | Mar 7, 2019 | N/A |
| Sep 30, 2018 | -$2.70 | -$2.50 | -$2.50 - -$2.40 | -8.00% | Miss | N/A | 2 | N/A | Nov 7, 2018 | N/A |
| Jun 30, 2018 | -$5.10 | -$3.60 | -$3.60 - -$2.00 | -41.67% | Miss | N/A | 2 | N/A | Aug 7, 2018 | N/A |
| Mar 31, 2018 | -$0.08 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Jun 15, 2018 | N/A |
| Dec 31, 2017 | -$0.18 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 30, 2018 | N/A |
| Mar 31, 2017 | -$0.02 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Jun 29, 2017 | N/A |
Estimates made before a stock split are shown on the same share basis as the reported EPS.
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$1.29, after -$13.20 the year before. It was -$0.20 for the year ended Dec 31, 2017, the oldest of the 9 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$1.29 | N/A |
| Dec 31, 2024 | -$13.20 | N/A |
| Dec 31, 2023 | -$9.83 | N/A |
| Dec 31, 2022 | -$6.60 | N/A |
| Dec 31, 2021 | -$9.75 | N/A |
| Dec 31, 2020 | -$8.91 | N/A |
| Dec 31, 2019 | -$11.30 | N/A |
| Dec 31, 2018 | -$8.18 | N/A |
| Dec 31, 2017 | -$0.20 | N/A |
Earnings Calls
The 7 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 7,600 words across 11 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 7,553 | 11 | |
| 2026Q2 | Jun 30, 2026 | 4,708 | 11 | |
| 2026Q1 | Mar 31, 2026 | 5,532 | 13 | |
| 2025Q3 | Sep 30, 2025 | 4,158 | 8 | |
| 2025Q2 | Jun 30, 2025 | 4,082 | 7 | |
| 2024Q4 | Dec 31, 2024 | 5,120 | 8 | |
| 2024Q2 | Jun 30, 2024 | 5,098 | 12 |
2026Q3 Earnings Call
Opening remarks
Kevin Gardner Host, Lifesci Advisors Thank you, Operator. Hello, everyone, and welcome to Verrica Pharmaceuticals' Third Quarter 2026 Corporate Update Conference Call. With me on the line this evening are Jayson Rieger, President and Chief Executive Officer; Noah Rosenberg, Chief Medical Officer; John Kirby, Interim Chief Financial Officer; and Chris Chapman, Chief Commercial Officer. As a reminder, during today's call, management will make forward-looking statements. These forward-looking statements are based on the company's current expectations and involve inherent risks and uncertainties. Verrica's actual results and the timing of events could differ materially from those anticipated in such forward-looking statements. Please see Verrica's SEC filings for important risk factors. Verrica cautions you not to place undue reliance on forward-looking statements and undertakes no duty or obligation to update any forward-looking statements as a result of new information, future events, or changes in expectations. In addition, during today's call, management will discuss certain non-GAAP financial measures. These non-GAAP financial measures are in addition to, and not a substitute for or superior to, measures of financial performance prepared in accordance with GAAP. There are a number of limitations related to the use of these non-GAAP financial measures compared to their closest GAAP equivalents. The earnings release that the company issued today includes GAAP-to-non-GAAP reconciliations for these measures and is also available on the Investor Relations section of Verrica's website. I'll now turn the call over to Verrica's President and CEO, Jayson Rieger.
Jayson Rieger President and Chief Executive Officer Thank you, Kevin. Good evening, everyone, and thank you for joining us for our third quarter 2026 corporate update call. We're so proud of our team's performance in the third quarter, as our commercial organization generated record YCANTH revenue for the second quarter in a row, while our research and development teams made major progress in our global Phase III program to expand YCANTH's label to common warts, the largest unmet need in dermatology by prevalence. During the quarter, we announced the completion of enrollment in the first pivotal trial in the Phase III program and greater than 50% enrollment in the second pivotal trial. Progress in each trial brings us closer to a possible expansion of YCANTH's label into what we believe could be a multibillion-dollar market for common warts. Following the end of the quarter, we announced that we have unlocked the remaining $15 million of borrowing commitment from the credit facility we entered into in August, as we met the predefined operational and performance milestones established in the facility. The non-dilutive capital now available to draw, as needed, is expected to allow us to complete both pivotal studies in the common warts program, with readouts from the studies expected in the first quarter and in mid-2027, respectively.
Frequently Asked Questions About VRCA
When is Verrica Pharmaceuticals's next earnings date?
Verrica Pharmaceuticals's next earnings report is expected for Mar 8, 2027.
Did VRCA beat earnings estimates last quarter?
No. Verrica Pharmaceuticals reported EPS of -$0.58 for the quarter ended Sep 30, 2026, below the -$0.50 estimate by 16.00%.
What EPS do analysts expect from VRCA next quarter?
The consensus EPS estimate for Verrica Pharmaceuticals for the quarter ending Dec 31, 2026 is -$0.49 from 9 analysts, with estimates from -$0.67 to -$0.33.
How often does VRCA beat earnings estimates?
Verrica Pharmaceuticals beat the EPS estimate in 6 of the last 8 quarters, with an average surprise of +29.48%.
VRCA pages: Overview, Earnings, Forecast, Financials, Competitors